Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 93

1.

Left atrial thrombus resolution in non-valvular atrial fibrillation or flutter: biomarker substudy results from a prospective study with rivaroxaban (X-TRA).

Miyazawa K, Pastori D, Hammerstingl C, Cappato R, Meng IL, Kramer F, Cohen A, Schulz A, Eickels MV, Lip GYH, Marin F.

Ann Med. 2018 Sep;50(6):511-518. doi: 10.1080/07853890.2018.1495337.

PMID:
29956554
2.

Left atrial thrombus resolution in atrial fibrillation or flutter: Results of a prospective study with rivaroxaban (X-TRA) and a retrospective observational registry providing baseline data (CLOT-AF).

Lip GY, Hammerstingl C, Marin F, Cappato R, Meng IL, Kirsch B, van Eickels M, Cohen A; X-TRA study and CLOT-AF registry investigators.

Am Heart J. 2016 Aug;178:126-34. doi: 10.1016/j.ahj.2016.05.007. Epub 2016 May 17.

3.
4.

Efficacy and safety of rivaroxaban on the resolution of left atrial/left atrial appendage thrombus in nonvalvular atrial fibrillation patients.

Ke HH, He Y, Lv XW, Zhang EH, Wei Z, Li JY.

J Thromb Thrombolysis. 2019 Aug;48(2):270-276. doi: 10.1007/s11239-019-01876-z.

PMID:
31165950
5.

Rationale and design of the RE-LATED AF--AFNET 7 trial: REsolution of Left atrial-Appendage Thrombus--Effects of Dabigatran in patients with Atrial Fibrillation.

Ferner M, Wachtlin D, Konrad T, Deuster O, Meinertz T, von Bardeleben S, Münzel T, Seibert-Grafe M, Breithardt G, Rostock T.

Clin Res Cardiol. 2016 Jan;105(1):29-36. doi: 10.1007/s00392-015-0883-7. Epub 2015 Jun 25.

PMID:
26109251
6.

Prothrombotic State in Patients With a Left Atrial Appendage Thrombus of Unknown Origin and Cerebrovascular Events.

Meus R, Son M, Sobczyk D, Undas A.

Stroke. 2016 Jul;47(7):1872-8. doi: 10.1161/STROKEAHA.116.012856. Epub 2016 Jun 14.

PMID:
27301942
7.

Incidence of left atrial abnormalities under treatment with dabigatran, rivaroxaban, and vitamin K antagonists.

Reers S, Agdirlioglu T, Kellner M, Borowski M, Thiele H, Waltenberger J, Reppel M.

Eur J Med Res. 2016 Oct 21;21(1):41.

8.

NOACs and atrial fibrillation: Incidence and predictors of left atrial thrombus in the real world.

Bertaglia E, Anselmino M, Zorzi A, Russo V, Toso E, Peruzza F, Rapacciuolo A, Migliore F, Gaita F, Cucchini U, De Divitiis M, Iliceto S, Stabile G.

Int J Cardiol. 2017 Dec 15;249:179-183. doi: 10.1016/j.ijcard.2017.07.048.

PMID:
29121724
10.

Prevalence and Resolution of Left Atrial Thrombus in Patients With Nonvalvular Atrial Fibrillation and Flutter With Oral Anticoagulation.

Niku AD, Shiota T, Siegel RJ, Rader F.

Am J Cardiol. 2019 Jan 1;123(1):63-68. doi: 10.1016/j.amjcard.2018.09.027. Epub 2018 Sep 26.

PMID:
30360887
11.

Comparison of diverse platelet activation markers as indicators for left atrial thrombus in atrial fibrillation.

Tarnowski D, Poitz DM, Plichta L, Heidrich FM, Wiedemann S, Ruf T, Mierke J, Löhn T, Jellinghaus S, Strasser RH, Ibrahim K, Pfluecke C.

Platelets. 2018 Jan;29(1):41-47. doi: 10.1080/09537104.2017.1293805. Epub 2017 Mar 13.

PMID:
28287031
12.

Intracardiac Hemostasis and Fibrinolysis Parameters in Patients with Atrial Fibrillation.

Tóth NK, Csanádi Z, Hajas O, Kiss A, Nagy-Baló E, Kovács KB, Sarkady F, Muszbek L, Bereczky Z, Csiba L, Bagoly Z.

Biomed Res Int. 2017;2017:3678017. doi: 10.1155/2017/3678017. Epub 2017 Jun 21.

13.

Efficacy of Direct Acting Oral Anticoagulant Drugs in Treatment of Left Atrial Appendage Thrombus in Patients With Atrial Fibrillation.

Fleddermann A, Eckert R, Muskala P, Hayes C, Magalski A, Main ML.

Am J Cardiol. 2019 Jan 1;123(1):57-62. doi: 10.1016/j.amjcard.2018.09.026. Epub 2018 Sep 26.

PMID:
30376957
14.

Prevalence of Left Atrial Thrombus Detection by Transesophageal Echocardiography: A Comparison of Continuous Non-Vitamin K Antagonist Oral Anticoagulant Versus Warfarin Therapy in Patients Undergoing Catheter Ablation for Atrial Fibrillation.

Frenkel D, D'Amato SA, Al-Kazaz M, Markowitz SM, Liu CF, Thomas G, Ip JE, Sharma SK, Yang H, Singh P, Lerman BB, Cheung JW.

JACC Clin Electrophysiol. 2016 Jun;2(3):295-303. doi: 10.1016/j.jacep.2016.01.004. Epub 2016 Mar 23.

15.

Growth differentiation factor 15 is associated with left atrial/left atrial appendage thrombus in patients with nonvalvular atrial fibrillation.

Hu XF, Zhan R, Xu S, Wang J, Wu J, Liu X, Li Y, Chen L.

Clin Cardiol. 2018 Jan;41(1):34-38. doi: 10.1002/clc.22844. Epub 2018 Jan 24.

17.

Activation of the endogenous coagulation system in patients with atrial flutter: relationship to echocardiographic markers of thromboembolic risk.

Kamath GS, Herweg B, Cotiga D, Pierce W, Cohen AJ, Chaudhry FA, Drejka ML, Steinberg JS.

Cardiol J. 2010;17(4):390-6.

18.

Dabigatran Therapy Resulting in the Resolution of Rivaroxaban-resistant Left Atrial Appendage Thrombi in Patients with Atrial Fibrillation.

Watanabe T, Shinoda Y, Ikeoka K, Minamisaka T, Fukuoka H, Inui H, Hoshida S.

Intern Med. 2017;56(15):1977-1980. doi: 10.2169/internalmedicine.56.8508. Epub 2017 Aug 1.

19.

Two-week administration of rivaroxaban resolved left atrial thrombus.

Kato T, Yasaka M, Yabuki T, Adachi T, Toyoda S, Inoue T.

J Cardiol Cases. 2014 Sep 26;10(6):238-240. doi: 10.1016/j.jccase.2014.08.006. eCollection 2014 Dec.

20.

[Evaluation of oral anticoagulation with rivaroxaban, in patients with new onset non valvular atrial fibrillation].

Neira V, Corbalán R, Pereira J, Panes O, Garayar B, Aizman A, Llevaneras S, Villarroel L.

Rev Med Chil. 2016 Sep;144(9):1103-1111. doi: 10.4067/S0034-98872016000900002. Spanish.

Supplemental Content

Support Center